Literature DB >> 29190235

Global Connections to Study Idiopathic Macular Telangiectasia Type 2.

Emily Y Chew1, Martin Friedlander2.   

Abstract

Entities:  

Mesh:

Year:  2018        PMID: 29190235      PMCID: PMC5726932          DOI: 10.1097/IAE.0000000000001921

Source DB:  PubMed          Journal:  Retina        ISSN: 0275-004X            Impact factor:   4.256


× No keyword cloud information.
  26 in total

1.  VOLUME-RENDERED ANGIOGRAPHIC AND STRUCTURAL OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY OF MACULAR TELANGIECTASIA TYPE 2.

Authors:  Richard F Spaide; Mihoko Suzuki; Lawrence A Yannuzzi; Alexandre Matet; Francine Behar-Cohen
Journal:  Retina       Date:  2017-03       Impact factor: 4.256

2.  MACULAR TELANGIECTASIA TYPE 2: Quantitative Analysis of a Novel Phenotype and Implications for the Pathobiology of the Disease.

Authors:  Mali Okada; Catherine A Egan; Tjebo F C Heeren; Adnan Tufail; Marcus Fruttiger; Peter M Maloca
Journal:  Retina       Date:  2018-01       Impact factor: 4.256

3.  Ciliary neurotrophic factor for macular telangiectasia type 2: results from a phase 1 safety trial.

Authors:  Emily Y Chew; Traci E Clemons; Tunde Peto; Ferenc B Sallo; Avner Ingerman; Weng Tao; Lawrence Singerman; Steven D Schwartz; Neal S Peachey; Alan C Bird
Journal:  Am J Ophthalmol       Date:  2014-12-19       Impact factor: 5.258

4.  FUNDUS-WIDE SUBRETINAL AND PIGMENT EPITHELIAL ABNORMALITIES IN MACULAR TELANGIECTASIA TYPE 2.

Authors:  Michael B Powner; Sasha M Woods; Meidong Zhu; Mark C Gillies; Paul S Bernstein; Gregory S Hageman; Grant M Comer; Catherine Egan; Marcus Fruttiger
Journal:  Retina       Date:  2018-01       Impact factor: 4.256

5.  EFFECT OF DARK ADAPTATION AND BLEACHING ON BLUE LIGHT REFLECTANCE IMAGING IN MACULAR TELANGIECTASIA TYPE 2.

Authors:  Mali Okada; Tjebo F C Heeren; Catherine A Egan; Vincent Rocco; Roberto Bonelli; Marcus Fruttiger
Journal:  Retina       Date:  2018-01       Impact factor: 4.256

6.  CORRELATION OF STRUCTURAL AND FUNCTIONAL OUTCOME MEASURES IN A PHASE ONE TRIAL OF CILIARY NEUROTROPHIC FACTOR IN TYPE 2 IDIOPATHIC MACULAR TELANGIECTASIA.

Authors:  Ferenc B Sallo; Irene Leung; Traci E Clemons; Tunde Peto; Emily Y Chew; Daniel Pauleikhoff; Alan C Bird
Journal:  Retina       Date:  2018-01       Impact factor: 4.256

7.  Idiopathic juxtafoveolar retinal telangiectasis.

Authors:  J D Gass; R T Oyakawa
Journal:  Arch Ophthalmol       Date:  1982-05

8.  Confocal blue reflectance imaging in type 2 idiopathic macular telangiectasia.

Authors:  Peter Charbel Issa; Tos T J M Berendschot; Giovanni Staurenghi; Frank G Holz; Hendrik P N Scholl
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-03       Impact factor: 4.799

9.  Medical characteristics of patients with macular telangiectasia type 2 (MacTel Type 2) MacTel project report no. 3.

Authors:  Traci E Clemons; Mark C Gillies; Emily Y Chew; Alan C Bird; Tunde Peto; Jie Jin Wang; Paul Mitchell; Wishal D Ramdas; Johannes R Vingerling
Journal:  Ophthalmic Epidemiol       Date:  2013-04       Impact factor: 1.648

10.  Baseline characteristics of participants in the natural history study of macular telangiectasia (MacTel) MacTel Project Report No. 2.

Authors:  Traci E Clemons; Marc C Gillies; Emily Y Chew; Alan C Bird; Tunde Peto; Maria J Figueroa; Molly W Harrington
Journal:  Ophthalmic Epidemiol       Date:  2010 Jan-Feb       Impact factor: 1.648

View more
  1 in total

Review 1.  Advancing Clinical Trials for Inherited Retinal Diseases: Recommendations from the Second Monaciano Symposium.

Authors:  Debra A Thompson; Alessandro Iannaccone; Robin R Ali; Vadim Y Arshavsky; Isabelle Audo; James W B Bainbridge; Cagri G Besirli; David G Birch; Kari E Branham; Artur V Cideciyan; Steven P Daiger; Deniz Dalkara; Jacque L Duncan; Abigail T Fahim; John G Flannery; Roberto Gattegna; John R Heckenlively; Elise Heon; K Thiran Jayasundera; Naheed W Khan; Henry Klassen; Bart P Leroy; Robert S Molday; David C Musch; Mark E Pennesi; Simon M Petersen-Jones; Eric A Pierce; Rajesh C Rao; Thomas A Reh; Jose A Sahel; Dror Sharon; Paul A Sieving; Enrica Strettoi; Paul Yang; David N Zacks
Journal:  Transl Vis Sci Technol       Date:  2020-06-03       Impact factor: 3.283

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.